Top Tweets for #botbal

8 months ago

Today, 4 PM ET: #Agenus Stakeholder Briefing on #BOTBAL global momentum + post-#ESMO2025 insights. With Dr. Michael Gordon & Prof. Alexander Eggermont. 🎥 Watch live: https://t.co/bNycRwBg46 #ImmunoOncology

Agenus_Bio's tweet photo. Today, 4 PM ET: #Agenus Stakeholder Briefing on #BOTBAL global momentum + post-#ESMO2025 insights.
With Dr. Michael Gordon & Prof. Alexander Eggermont.
🎥 Watch live: https://t.co/bNycRwBg46
#ImmunoOncology https://t.co/915iS1uZLU

343

8 months ago

Emerging survival plateaus with BOT/BAL across advanced solid tumors. Presented by Dr. Michael Gordon at #ESMO2025 from a 400+ patient Phase 1b study of refractory cancers. See the full presentation → https://t.co/RrXNv940FO #BOTBAL #ImmunoOncology

$Agenus_Bio's tweet photo. Emerging survival plateaus with BOT/BAL across advanced solid tumors. Presented by Dr. Michael Gordon at #ESMO2025 from a 400+ patient Phase 1b study of refractory cancers. See the full presentation → https://t.co/RrXNv940FO #BOTBAL #ImmunoOncology https://t.co/tnbnyNxw28$

763

8 months ago

New #ESMO2025 data: BOT/BAL shows 39% of patients alive at 2 years across multiple refractory tumors, including those who failed prior IO. Durable hope for patients left behind by first-gen immunotherapy. Read the release: https://t.co/OLXJ6Yn4hn #ImmunoOncology #BOTBAL

$Agenus_Bio's tweet photo. New #ESMO2025 data: BOT/BAL shows 39% of patients alive at 2 years across multiple refractory tumors, including those who failed prior IO. Durable hope for patients left behind by first-gen immunotherapy. Read the release: https://t.co/OLXJ6Yn4hn #ImmunoOncology #BOTBAL https://t.co/xj8OlcTdCu$

8 months ago

Join us Oct 21, 4PM ET for the next #Agenus Stakeholder Briefing—moderated by Dr. Garo Armen. Hear from industry leaders report post #ESMO2025 BOT/BAL data and learn about expanding access. 🎥 Watch live → https://t.co/bNycRwAIey #BOTBAL #ImmunoOncology

Agenus_Bio's tweet photo. Join us Oct 21, 4PM ET for the next #Agenus Stakeholder Briefing—moderated by Dr. Garo Armen.
Hear from industry leaders report post #ESMO2025 BOT/BAL data and learn about expanding access.
🎥 Watch live → https://t.co/bNycRwAIey
#BOTBAL #ImmunoOncology https://t.co/xFIKq5wTPI

453

9 months ago

Missed the Agenus Stakeholder Briefing? Catch the highlights in 4 minutes: ✔️ CRC crisis & urgent patient needs ✔️ Our bold vision for IO ✔️ BOT/BAL & Phase 3 BATTMAN ✔️ Partnership momentum Watch below: #ImmunoOncology #CRC #Biotech #BOTBAL #Agenus

9 months ago

France grants reimbursed early access to BOT/BAL for patients with metastatic MSS colorectal cancer under its Accès Compassionnel (AAC) program. Read More: https://t.co/IYzQBvZEJ5 #ColorectalCancer #Immunotherapy #BOTBAL #France #AAC #Oncology

Agenus_Bio's tweet photo. France grants reimbursed early access to BOT/BAL for patients with metastatic MSS colorectal cancer under its Accès Compassionnel (AAC) program.
Read More: https://t.co/IYzQBvZEJ5
#ColorectalCancer #Immunotherapy #BOTBAL #France #AAC #Oncology https://t.co/czlfO1t6Kc

Zynext Ventures @ZynextVentures

10 months ago

📢 NEW LINK: Don’t miss our Virtual Stakeholder Briefing on Aug 27 @ 4PM ET! https://t.co/bNycRwAIey We'll cover our progress, BOT/BAL data, BATTMAN trial preview + more. #ImmunoOncology #BOTBAL #Biotech $AGEN

Agenus_Bio's tweet photo. 📢 NEW LINK: Don’t miss our Virtual Stakeholder Briefing on Aug 27 @ 4PM ET!
https://t.co/bNycRwAIey

We'll cover our progress, BOT/BAL data, BATTMAN trial preview + more.
#ImmunoOncology #BOTBAL #Biotech $AGEN https://t.co/nPVv69saXZ

675

about 1 year ago

Zynext Ventures invests in @Agenus_Bio to accelerate their groundbreaking immunotherapy BOT/BAL. @ZydusUniverse #ZynextVentures #Agenus #BiotechInvestment #CancerResearch #HealthcareInnovation #VentureCapital #immunooncology #Cancer #Oncology #Biotech #ASCO25 #ESMO #BOTBAL

ZynextVentures's tweet photo. Zynext Ventures invests in @Agenus_Bio to accelerate their groundbreaking immunotherapy BOT/BAL.

@ZydusUniverse #ZynextVentures #Agenus #BiotechInvestment #CancerResearch #HealthcareInnovation #VentureCapital #immunooncology #Cancer #Oncology #Biotech #ASCO25 #ESMO #BOTBAL https://t.co/hNmzOaEkRJ

Jennifer Buell

@jbuell01

about 1 year ago

To our Emeryville & Berkeley teams: you embody integrity and excellence, you now anchor global biotech trade! #BOTBAL #biotech #immunotherapy #USIndia #manufacturing #globalhealth

349

OncoDaily GI

@OncoDailyGI

about 1 year ago

TCR dynamics after first dose BOTBAL are predictive for response - @GJRas https://t.co/zcU1CbNRcf #ASCO25 #BOTBAL #Cancer #FightAgainstCancer #Gastroenterology #GastrointestinalOncology #MedEd #MedX #GlobalFightAgainstCancer #OncoDaily #Oncology

239

Gertjan Rasschaert @GJRas

about 1 year ago

🧐 Can you predict who’s responding to #BOTBAL and who isn’t? Discover it next week at #ASCO25! 🙋‍♂️ See you on: Saturday 31st of May, 09:00AM to 12:00PM #CRC poster session, Hall A Poster Bd 196 - Abstract No 3527 @UZLeuven @KU_Leuven @OmniscopeAI @Agenus_Bio @ASCO

GJRas's tweet photo. 🧐 Can you predict who’s responding to #BOTBAL and who isn’t? Discover it next week at #ASCO25!

🙋‍♂️ See you on:
Saturday 31st of May, 09:00AM to 12:00PM #CRC poster session, Hall A
Poster Bd 196 - Abstract No 3527

@UZLeuven @KU_Leuven @OmniscopeAI @Agenus_Bio @ASCO https://t.co/F6nwhsbPDN

504

Gertjan Rasschaert @GJRas

over 1 year ago

#CRC highlights from @ASCO #GI25: #8HW, #breakwater, #alascca, #bespoke, #botbal metastatic and neoadjuvant, @Agenus_Bio, etc. Bridging towards our now open #AZUR4 @GSK neoadjuvant trial in #pMMR #MSS CRC at @UZLeuven

MediMix

@Medi_Mix

over 1 year ago

🚨Highlights from #ASCOGI2025! Dr @GJRas unveils key advances in colorectal cancer. From immunotherapy breakthroughs to predictive biomarkers and preventive strategies, catch all the latest insights.

447

363

OncoDaily

@oncodaily

almost 2 years ago

I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan @GevTamamyan @Agenus_Bio https://t.co/ZmXeSORwfn #oncology #cancer #oncodaily #colorectalcancer #botbal #agenus

oncodaily's tweet photo. I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan @GevTamamyan @Agenus_Bio

https://t.co/ZmXeSORwfn

#oncology #cancer #oncodaily #colorectalcancer #botbal #agenus https://t.co/cVG2jsYbrQ

304

OncoDaily

@oncodaily

almost 2 years ago

Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day @ODayMD @Agenus_Bio https://t.co/q1FRqDbhxk #agenus #botensilimab #balstilimab #colorectalcancer #botbal #StevenODay #cancer #oncology #oncodaily

oncodaily's tweet photo. Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day @ODayMD @Agenus_Bio

https://t.co/q1FRqDbhxk

#agenus #botensilimab #balstilimab #colorectalcancer #botbal #StevenODay #cancer #oncology #oncodaily

671

Gertjan Rasschaert @GJRas

almost 2 years ago

1/2 🪺 #NEST is true pioneering work by both @pashtoonkasi and @Agenus, unlocking #MSS #CRC with next generation #IO (#BOTBAL) in the #neoadjuvant setting. 📌 Even if patient numbers are still low atm, a true paradigm shift is waiting for us. #ESMOGI24 @myESMO @oncodaily

GJRas's tweet photo. 1/2

🪺 #NEST is true pioneering work by both @pashtoonkasi and @Agenus, unlocking #MSS #CRC with next generation #IO (#BOTBAL) in the #neoadjuvant setting.

📌 Even if patient numbers are still low atm, a true paradigm shift is waiting for us.

#ESMOGI24 @myESMO @oncodaily https://t.co/WPLlaqPrdu

over 3 years ago · California

@HPolymenis @Aiims1742 @KReissMD @PeterHoseinMD & others have shown that not all immunotherapies are alike. PD1⛔️➕PARP⛔️ very different🆚CTLA4⛔️combinations. Ongoing #BOTBAL studies are also evaluating if the BAL is necessary and what dose of BOT. T300➕D single dose continues to intrigues me. #GI23

pashtoonkasi's tweet photo. @HPolymenis @Aiims1742 @KReissMD @PeterHoseinMD & others have shown that not all immunotherapies are alike.

PD1⛔️➕PARP⛔️ very different🆚CTLA4⛔️combinations.

Ongoing #BOTBAL studies are also evaluating if the BAL is necessary and what dose of BOT. T300➕D single dose continues to intrigues me. #GI23 https://t.co/JyCzpHNESn

344

over 3 years ago · San Francisco

@RenoHemonc @OncLive @ASCO @MayoCancerCare @OncoAlert @NRGonc @TGeorgeMD @RenoHemonc your wish is my command. 🧞 My investigator initiated trial got IRB approved this week! @ASCO #GI23 Here’s us building on the exciting data on #immunotherapy (with #BOTBAL) in the neoadjuvant space for #colorectalcancer. #CRCSM #ctDNA🩸🧬 https://t.co/lIBkAeoHR2

pashtoonkasi's tweet photo. @RenoHemonc @OncLive @ASCO @MayoCancerCare @OncoAlert @NRGonc @TGeorgeMD @RenoHemonc your wish is my command. 🧞

My investigator initiated trial got IRB approved this week! @ASCO #GI23

Here’s us building on the exciting data on #immunotherapy (with #BOTBAL) in the neoadjuvant space for #colorectalcancer.

#CRCSM #ctDNA🩸🧬

https://t.co/lIBkAeoHR2 https://t.co/3l8GP5jk7a

over 3 years ago · Manhattan

Imitation is the sincerest form of flattery. Here’s us building on the exciting data on #immunotherapy (with BOT/BAL) in the neoadjuvant space for #colorectalcancer. NEST-1 is 1st of several efforts following NICHE-1. #CRCSM #ctDNA🩸🧬 Link: https://t.co/lIBkAeoHR2 Thoughts?

pashtoonkasi's tweet photo. Imitation is the sincerest form of flattery.

Here’s us building on the exciting data on #immunotherapy (with BOT/BAL) in the neoadjuvant space for #colorectalcancer.

NEST-1 is 1st of several efforts following NICHE-1.

#CRCSM #ctDNA🩸🧬
Link: https://t.co/lIBkAeoHR2

Thoughts? https://t.co/yRVMpts0iq